Hutch News
Results per Page:
New Science Spotlight Articles
Every month, Fred Hutch postdoc writer/editors summarize two papers from each of our scientific divisions to stimulate collaborations across campus
March 20, 2023
Merkel cell carcinoma researcher Dr. Nick Salisbury named Brave Fellow
Rare skin cancer is focus of work by Fred Hutch scientist who will receive support honoring runner Gabe Grunewald
Dr. Denise Galloway elected Fellow of the American Association for Cancer Research Academy
Cancer biologist contributed basic and translational insights that made the cancer-preventive HPV vaccine possible
Dr. Martin 'Mac' Cheever, cancer immunotherapy expert, receives distinguished service award
Honor recognizes his work establishing Cancer Immunotherapy Trials Network
$12M NIH grant to study rare, aggressive skin cancer
Fred Hutch, UW researchers hope to improve immunotherapies for people with Merkel cell carcinoma
On immunotherapy trial, long-term survivors of deadly skin cancer point to a hopeful future
Once unheard-of survival rates seen among patients with advanced Merkel cell carcinoma
Seattle team pivotal to FDA OK on drug for rare skin cancer
UW Medicine and Fred Hutch had key roles in clinical trial of immunotherapy option for often-lethal Merkel cell cancer
Immune booster may awaken body’s defenses against skin cancer
First-in-human pilot of experimental immunotherapy in Merkel cell carcinoma
Molecular mechanisms of late cancer relapse
from the Chapuis lab, Clinical Research Division
Revealing a new way that cancer can evade immunotherapy — and, maybe, how to stop it
How a new technology solved a mystery and honors one man’s legacy
Cancer cells evade immunotherapy by hiding telltale marker, suggesting how to stop relapse
A Nature Communications report explains why some Merkel cell carcinoma patients treated with immunotherapy see their cancers shrink at first but then come back.
New guide helps clinicians navigate immunotherapy revolution in Merkel cell carcinoma
‘Real-world’ review accompanies new clinical care guidelines in rare skin cancer
Fred Hutch at ASCO
Immunotherapy advances, insights into health economics and leadership awards dominate oncology gathering
Immunotherapy has long-term benefit for patients with advanced Merkel cell carcinoma
‘Incredibly big change’ in treatment of deadly skin cancer, new data show
10 highlights of Fred Hutch science in 2017
A look back at notable discoveries in cancer immunotherapy, HIV prevention and more
Galloway receives NCI Outstanding Investigator Award
Leader in HPV research will work to improve detection, prevention and treatment of virally caused cancers
Integrated approach to overcome pathogen-associated malignancies
Dr. Denise Galloway heads new collaborative center to study prevention and treatment of cancers linked to infectious agents
Triple therapy for rare skin cancer shows promise in small, early-stage trial
Combo of T-cell therapy, newly FDA-approved drug and another immune booster kept cancer at bay for three of four patients with metastatic Merkel cell carcinoma
With immunotherapy trial, ‘a real paradigm shift’ in rare skin cancer
Investigators report ‘extraordinarily’ long-lasting treatment responses in patients with chemo-resistant, metastatic Merkel cell carcinoma